AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022

AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022

Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday, Dec. 5, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen’s R&D team, will discuss the Phase 1 data from AMG 133, a novel bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule.

The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors, and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, under Investors. Information regarding presentation times, webcast availability, and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

Source link: https://www.amgen.com/